XTL Biopharmaceutica Cash Per Share vs. Book Value Per Share

XTLB Stock  ILS 5.90  0.10  1.72%   
Based on the key profitability measurements obtained from XTL Biopharmaceutica's financial statements, XTL Biopharmaceuticals may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess XTL Biopharmaceutica's ability to earn profits and add value for shareholders.
For XTL Biopharmaceutica profitability analysis, we use financial ratios and fundamental drivers that measure the ability of XTL Biopharmaceutica to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well XTL Biopharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between XTL Biopharmaceutica's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of XTL Biopharmaceuticals over time as well as its relative position and ranking within its peers.
  
Check out Your Current Watchlist.
Please note, there is a significant difference between XTL Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if XTL Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, XTL Biopharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

XTL Biopharmaceuticals Book Value Per Share vs. Cash Per Share Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining XTL Biopharmaceutica's current stock value. Our valuation model uses many indicators to compare XTL Biopharmaceutica value to that of its competitors to determine the firm's financial worth.
XTL Biopharmaceuticals is rated below average in cash per share category among its peers. It is rated below average in book value per share category among its peers creating about  0.90  of Book Value Per Share per Cash Per Share. The ratio of Cash Per Share to Book Value Per Share for XTL Biopharmaceuticals is roughly  1.11 . Comparative valuation analysis is a catch-all model that can be used if you cannot value XTL Biopharmaceutica by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for XTL Biopharmaceutica's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

XTL Book Value Per Share vs. Cash Per Share

Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

XTL Biopharmaceutica

Cash Per Share

 = 

Total Cash

Average Shares

 = 
0.01 X
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

XTL Biopharmaceutica

Book Value per Share

 = 

Common Equity

Average Shares

 = 
0.01 X
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.

XTL Book Value Per Share Comparison

XTL Biopharmaceutica is currently under evaluation in book value per share category among its peers.

XTL Biopharmaceutica Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in XTL Biopharmaceutica, profitability is also one of the essential criteria for including it into their portfolios because, without profit, XTL Biopharmaceutica will eventually generate negative long term returns. The profitability progress is the general direction of XTL Biopharmaceutica's change in net profit over the period of time. It can combine multiple indicators of XTL Biopharmaceutica, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Ramat Gan, Israel. XTL BIOPHARMACEUTI is traded on Tel Aviv Stock Exchange in Israel.

XTL Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on XTL Biopharmaceutica. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of XTL Biopharmaceutica position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the XTL Biopharmaceutica's important profitability drivers and their relationship over time.

Use XTL Biopharmaceutica in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if XTL Biopharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in XTL Biopharmaceutica will appreciate offsetting losses from the drop in the long position's value.

XTL Biopharmaceutica Pair Trading

XTL Biopharmaceuticals Pair Trading Analysis

The ability to find closely correlated positions to XTL Biopharmaceutica could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace XTL Biopharmaceutica when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back XTL Biopharmaceutica - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling XTL Biopharmaceuticals to buy it.
The correlation of XTL Biopharmaceutica is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as XTL Biopharmaceutica moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if XTL Biopharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for XTL Biopharmaceutica can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your XTL Biopharmaceutica position

In addition to having XTL Biopharmaceutica in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Government Funds Thematic Idea Now

Government Funds
Government Funds Theme
Funds or Etfs that invest in fixed income securities issued by national government to finance government spending or to facilitate Federal Reserve monetary policies. The Government Funds theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Government Funds Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in XTL Stock

To fully project XTL Biopharmaceutica's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of XTL Biopharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include XTL Biopharmaceutica's income statement, its balance sheet, and the statement of cash flows.
Potential XTL Biopharmaceutica investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although XTL Biopharmaceutica investors may work on each financial statement separately, they are all related. The changes in XTL Biopharmaceutica's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on XTL Biopharmaceutica's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.